[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Clinical Challenges in Otolaryngology
February 16, 2009

Use of Cidofovir for Treatment of Recurrent Respiratory Papillomatosis

Author Affiliations

Author Affiliation: Departments of Otolaryngology and Pediatrics, Eastern Virginia Medical School, Norfolk.



Arch Otolaryngol Head Neck Surg. 2009;135(2):198-201. doi:10.1001/archoto.2008.539

Hypothesis: Intralesional cidofovir should be routinely considered in the treatment of recurrent respiratory papillomatosis (RRP).

Although surgical management remains the mainstay of therapy for RRP, ultimately as many as 20% of patients with the disease will require some form of adjuvant therapy.1The most widely adopted current criteria for initiating adjuvant therapy are a surgery requirement of more than 4 procedures per year, distal multisite spread of disease, and/or rapid regrowth of papilloma disease with airway compromise.2At the present time, there are no medications approved by the US Food and Drug Administration (FDA) with an indication for treatment of RRP.

First Page Preview View Large
First page PDF preview
First page PDF preview